Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content [Randomisierte, placebokontrollierte, klinische Crossover Studie um den Effekt von Dapagliflozin auf die mikrovaskuläre und makrovasculäre Zirkulation und den Natriumgehalt des Körpers zu analysieren.]

Trial Profile

Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content [Randomisierte, placebokontrollierte, klinische Crossover Studie um den Effekt von Dapagliflozin auf die mikrovaskuläre und makrovasculäre Zirkulation und den Natriumgehalt des Körpers zu analysieren.]

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Diabetic retinopathy; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Oct 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 03 Mar 2014 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top